Integer (NYSE:ITGR) Reaches New 12-Month High at $119.51

Integer Holdings Co. (NYSE:ITGR)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $119.51 and last traded at $119.48, with a volume of 33983 shares. The stock had previously closed at $115.77.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ITGR. CL King began coverage on shares of Integer in a research report on Thursday, March 14th. They set a “buy” rating and a $137.00 price target on the stock. Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $105.00 to $135.00 in a research report on Monday. KeyCorp boosted their price target on shares of Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 9th. Finally, Benchmark raised their target price on shares of Integer from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $120.50.

Integer Price Performance

The company’s 50 day moving average is $111.09 and its 200-day moving average is $97.94. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of 44.35, a P/E/G ratio of 1.46 and a beta of 1.10.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.05. The firm had revenue of $413.15 million during the quarter, compared to the consensus estimate of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the business posted $1.11 earnings per share. Equities research analysts anticipate that Integer Holdings Co. will post 5.28 earnings per share for the current year.

Institutional Investors Weigh In On Integer

Several hedge funds have recently bought and sold shares of ITGR. Covestor Ltd increased its holdings in shares of Integer by 420.6% during the first quarter. Covestor Ltd now owns 328 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 265 shares during the period. Blue Trust Inc. increased its holdings in shares of Integer by 483.3% during the fourth quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 377 shares during the period. State of Wyoming increased its holdings in shares of Integer by 129.5% during the fourth quarter. State of Wyoming now owns 840 shares of the medical equipment provider’s stock worth $58,000 after purchasing an additional 474 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Integer by 28.5% during the first quarter. Tower Research Capital LLC TRC now owns 775 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 172 shares during the period. Finally, Principal Securities Inc. bought a new position in shares of Integer during the fourth quarter worth approximately $67,000. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.